Tenofovir may reduce risk of liver cancer in patients with HBV infection
the ONA take:
A new study published online ahead of print in the journal Cancer has shown that long-term therapy with tenofovir disoproxil fumarate (TDF) was associated with a decreased incidence of hepatocellular carcinoma among patients with chronic hepatitis B virus (HBV) infection without cirrhosis.
According to the American Cancer Society, there will be nearly 36,000 new cases of liver cancer diagnosed in the 2015 and about 24,550 people will die from the disease.
For the study, researchers analyzed data from the pivotal TDF registration studies that followed patients for 384 weeks. Of the 634 patients included for analysis, 152 had cirrhosis and 482 did not. During the study period, 14 patients developed hepatocellular carcinoma.
Results showed that the incidence of hepatocellular carcinoma was significantly lower than predicted among patients without cirrhosis.
TDF is an oral antiviral medication used to treat HIV infection in combination with other drugs and chronic HBV infection.
Long-term therapy with tenofovir was associated with a decreased incidence of HCC among patients with chronic HBV infection without cirrhosis.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|